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Vascular endothelial cell growth factors (VEGF)-A, -C and -D have potent angio and lymphangiogenic functions in experimental
models, although their role in the progression of human breast cancer is unclear. The aims of the current study were to examine the
relationship between the expression of the aforementioned growth factors with the angio and lymphangiogenic characteristics of
breast cancer, and to assess their suitability as potential prognostic factors. Paraffin-embedded sections of 177 primary invasive breast
cancer, with complete clinical follow-up information for 10 years, were stained for VEGF-A, -C, -D, podoplanin and CD34 using
standard immunohistochemical approaches. The expression of the growth factors was correlated with clinicopathological criteria and
patients’ survival. Lymph vessel density (LVD) and microvessel density (MVD) were assessed and correlated with expression of the
growth factors. Vascular endothelial cell growth factor-A, -C and -D were highly expressed in 40, 37 and 42% of specimens,
respectively. High expression of VEGF-A and - C, but not of -D, was associated with a higher LVD (P¼0.013 and P¼0.014,
respectively), a higher MVD (Po0.001 and P¼0.002, respectively), the presence of lymph node metastasis (Po0.001 and Po0.001,
respectively), distant metastasis (P¼0.010 and P¼0.008, respectively) and a shorter Overall Survival (P¼0.029 and 0.028,
respectively). In conclusion, breast cancers that express high levels of VEGF-A and -C are characterised by a poor prognosis, likely
through the induction of angio and lymphangiogenesis. Examination of expression of VEGF-A and -C in breast cancer may be
beneficial in the identification of a subset of tumours that have a higher probability of recurrence and metastatic spread.
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Angiogenesis, the formation of new blood vessels, and lymph-
angiogenesis, the formation of new lymphatics, are complex
processes in which different signalling systems work together; the
main system being the vascular endothelial cell growth factor
(VEGF) family of proteins and the associated receptors. This
system is composed of a family of glycoprotein growth factors;
VEGF-A, -B, -C, -D, -E and the placenta growth factor (PLGF)
(Ferrara and Davis-Smyth, 1997). They bind selectively, with
different affinities to three receptors that belong to the superfamily
of receptor tyrosine kinases; VEGFR-1, -2 and -3. Both VEGFR-1
and VEGFR-2 are expressed on the surface of blood endothelial
cells (BECs). Vascular endothelial cell growth factor receptor-3 is
expressed throughout both blood and lymphatic vasculature
during embryological development and in tumour tissues, however
in normal adult tissues it is restricted to lymphatic endothelial cells
(LECs) (Partanen and Paavonen, 2001).
Vascular endothelial cell growth factor-A, a multifunctional
cytokine secreted by a large variety of cells, is known to play an
essential role in vasculogenesis and angiogenesis (Fox et al, 2001).
During transcription, it undergoes alternative splicing, yielding
multiple mature glycoprotein isoforms with different amino-acid
lengths (VEGF-A165, -A121, -A189 and -A206) that are capable of
inducing proliferation and migration of endothelial cells (ECs)
(Ferrara and Bunting, 1996). Expression of VEGF-A has been
found to be upregulated and suggested to be associated with
progression of certain types of human tumours such as lung (Han
et al, 2001), eosophageal (Kleespies et al, 2005) and colorectal
cancers (Des Guetz et al, 2006). Studies on human breast cancer
reported a significant relationship between high expression of
VEGF-A and tumours with higher proliferation rate, negative
oestrogen receptor status (Fuckar et al, 2006) and poor prognosis
(Linderholm et al, 1999).
The role of VEGF-A as a potent angiogenic factor in malignant
tumours is well established, but it has long been thought that it
had no influence upon lymphangiogenesis. It has recently been
reported, however, that VEGF-A can induce lymphangiogenesis as
well as angiogenesis (Nagy et al, 2002). The relationship between
the expression of VEGF-A and lymphangiogenesis in breast cancer
has not been studied and is a component of the current study.
VEGF-C and -D have potent lymphangiogenic functions
through stimulation of VEGFR-3 on the surface of LECs. They
are produced in pro–prepeptide dimers that undergo proteolysis
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sin the extracellular matrix (ECM) to a mature form that has much
higher affinity to VEGFR-3, inducing lymphangiogenesis, but can
also bind VEGFR-2, inducing angiogenesis (Joukov et al, 1996).
Overexpression of VEGF-C and -D in experimental tumour models
has been found to be significantly associated with the formation
of new lymphatics (Skobe et al, 2001; Stacker et al, 2001; Von
Marschall et al, 2005), however, their effect in human cancers is a
matter of controversy with some studies finding a significant
association with tumour angiogenesis, lymphangiogenesis, lymph
node (LN) status and prognosis (Nakamura et al, 2003a, 2005) and
others no relationships (Currie et al, 2004).
The mainstay of assessment of tumour vascularity has been
counting the number of immunohistochemically identified micro-
vessels in vascular hot spots, known as the microvessel density
(MVD) (Weidner et al, 1992), using vascular markers such as
factor VIII-related antigen, CD34 and CD31, with a recent review
recommending procedures that should be followed for the
assessment of MVD in breast cancer (Fox and Harris, 2004). The
assessment of lymphatic characteristics in malignant tumours has
historically been difficult owing to the lack of availability of
lymphatic-specific markers. Such markers have recently been
characterised and become commercially available. Markers
include podoplanin, D2-40, LYVE-1 and Prox-1. The count of
positively stained vessels per tumour area, lymph vessel
density (LVD), has been used to assess lymphangiogenic
characteristics in tumour specimens (Rodriguez-Niedenfuhr
et al, 2001; Sahni et al, 2005). High MVD (Weidner et al, 1991;
Bevilacqua et al, 1995; Toi et al, 1995b; Choi et al, 2005) and high
LVD (Choi et al, 2005) in breast cancer have been reported to be
associated with more aggressive tumour behaviour and poorer
survival.
Although a number of studies have examined the relationship
between the expression of each of the VEGFs with patient
prognosis, angiogenic and lymphangiogenic characteristics in
breast cancer, examination of the expression of all three, together,
in a well-characterised series of breast cancers with long-term
follow-up has not been conducted. The aims of the current study
were to: (a) investigate the expression of VEGF-A, -C and -D in
human breast cancer via immunohistochemistry, (b) examine the
tumour lymphatic and vascular characteristics by counting
lymph vessels/area to determine LVD and counting blood vessels
via the Chalkley method to assess MVD and (c) conduct
correlations between expression of the growth factors in relation
to patient clinicopathological data, survival, lymphangiogenesis
and angiogenesis to examine the role that they play in the
regulation of such processes and in the progression of breast
cancer.
MATERIALS AND METHODS
Patients and tissue samples
One hundred and seventy-seven paraffin-embedded archival
specimens of primary invasive breast cancer were retrieved from
the Department of Histopathology, Nottingham University Hospitals,
City Hospital Campus. The median age of patients at time of
diagnosis was 57 years (range 32–70 years). Fifty-one patients
(28.2%) were younger than 50 years. Sixty-five (36.7%) of the
specimens were o1.5cm. At the time of primary diagnosis, 52
(29.4%) patients had positive LNs. Most of the tumours were stage
I( n¼121, 68.4%) and stage II (n¼43, 24.3%) disease. Complete
clinical follow-up information was available for all 177 patients,
with ethical approval obtained for analysis from Nottingham Local
Research Ethics Committee (REC C2020313). The median follow-
up period was 96 months. Forty-one patients developed regional
recurrence by the time of the last follow-up and 16 patients died
from breast cancer.
Immunohistochemistry
Staining with two lymphatic markers, D2-40 (SIGNET, 730-16) and
podoplanin was carried out on paraffin-embedded blocks of tonsil,
LN and breast cancer tissues. Recently, however, Schacht et al
(2005) found that D2-40 and podoplanin detect the same protein
on LECs. As both markers showed the same intensity of staining,
and the same pattern, either can be used to generate the same
results.
A representative, paraffin-embedded section from each speci-
men was stained with Podoplanin (polyclonal Ab, AngioBio, CA,
USA, 11-003, 1:100 dilution), CD34 (polyclonal Ab, SEROTEC,
Oxford, UK, MCAP547, 1:500 dilution), VEGF-A (monoclonal Ab,
LAB VISION, CA, USA, RM-9128-S, 1:100 dilution), VEGF-C
(polyclonal Ab, ZYMED, CA, USA, 18-2255, 1:75 dilution) and
VEGF-D (monoclonal Ab, R&D, Abingdon, UK, MAB286 in 1:400
dilution). Briefly, 4-mm-thick sections were deparaffinised with
xylene and rehydrated. Antigen retrieval for CD34, VEGF-A, -C
and -D was achieved by incubating sections in 0.01moll
 1 sodium
citrate buffer (pH 6.0) in a 800W microwave for 20min; 10min at
800W then 10min at 100W. Podoplanin did not require antigen
retrieval. Endogenous hydrogen peroxidase (H2O2) reactivity was
blocked with 3% H2O2. Nonspecific reactions were blocked by use
of normal swine serum for 20min. Sections were incubated for 1h
at room temperature for all primary antibodies except for VEGF-D
that was incubated overnight at 41C. After washing, sections were
treated with commercial biotinylated secondary anti-immuno-
globulin, followed by avidin coupled to biotinylated horseradish
peroxidase, at room temperature, according to the manufacturer’s
instructions using streptABC kit (StreptABComplex/HRP Duet,
Mouse/Rabbit kit, DAKO Corporation, Denmark, K0492). Im-
munohistochemical reactions were developed with 3,30 diamino-
benzidine as the chromogenic peroxidase substrate (DAKO,
K3468). Sections were then counterstained with Myer’s haematox-
ylein, dehydrated, fixed in xylene and mounted with DPX. Sections
from placenta were used as a positive control, for VEGFs and
CD34, and sections from LN were used for podoplanin. For
negative controls, sections were stained using the same procedure
after omitting primary antibody.
Evaluation of growth factor expression
Expression of VEGF-A, -C and -D was assessed semiquantitatively
using an immunohistochemical score (H score). Staining intensity
was given four grades: none (0), weak (1), moderate (2) and strong
(3). H score was calculated by multiplying the percentage of
positive carcinoma cells by the staining intensity, this gave an H
score ranging from 0 to 300. The median of the score was selected
as the cutoff level according to which tumours were categorised
into low- and high-expressing tumours. Median values were 160
for VEGF-A, 140 for VEGF-C and 130 for VEGF-D. This method, in
selecting an appropriate cutoff level, has been used in previous
studies (Yang et al, 2002).
Assessment of LVD
The commonly used method for assessment of density of lymph
vessels in tumour has been counting the number of immunohis-
tochemically identified lymphatics in the most vascularised
tumour areas; hot spots (Giorgadze et al, 2004; Koskinen et al,
2005; Nakamura et al, 2005). In the present study, a modified
procedure was used, where LVD was assessed by counting all
lymph vessels in the whole tumour section, using  100
magnification with a surface area of 3.46mm
2. Although easier
to use the  200 magnification to assess LVD, the strong staining
of lymphatics allowed easy recognition of vessels at  100,
especially when examining the whole tumour section. The sum
of lymph vessels was divided by the sum of the surface area of all
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scounted fields to adjust LVD per mm
2. Lymph vessel density was
presented as number of lymph vessels per mm
2. Although more
labour intensive, such methodology allows a more accurate
assessment of lymphatic density. The distribution of lymphatics
and prevalence of lymphovascular invasion will be the focus of a
separate report.
Assessment of MVD
Sections stained with CD34 were used for the evaluation of MVD
using the Chalkley counting method. Each section was first
scanned at low-power magnification ( 40) to select the most
vascularised areas; three hot spots were selected. Two authors first
examined 10% of specimens to agree on which fields to be used as
hot spots. A 25-point Chalkley eyepiece graticule was applied to
each hot spot and oriented to permit the maximum number of
points to hit on, or within the areas of immunohistochemically
highlighted microvessel using  200 magnification. A Chalkley
count for an individual tumour was taken as the mean value of the
three graticule counts (Fox and Harris, 2004).
For assessment of LVD, MVD and expression of VEGFs, a
second investigator also blinded to the patients’ clinical character-
istics and survival data, independently assessed 20% of sections. A
k40.90 was obtained, indicating a very good correlation between
observers.
Statistical analysis
Four levels of statistics were performed using SPSS for windows,
version 13: (1) Mann–Whitney tests were conducted to compare
means of LVD and MVD (as a continuous data) between different
clinicopathological groups and (2) specimens were divided into
two categories according to the median values of LVD and MVD.
The association between expression of VEGFs and LVD, MVD and
clinicopathological criteria was evaluated in univariate analysis
using a 2 2 table and w
2 test, (3) survival analysis of disease-free
interval (DFI) and overall survival (OS) was accomplished using
the Kaplan–Meier method and the statistical significance of
differences in the cumulative survival curves between groups was
evaluated by the long-rank test. Multivariate survival analysis was
performed using the Cox’s proportional hazard method and (4) the
Kappa (k) agreement test was used to assess agreement between
observers. All statistical analyses were two sided with significance
defined as Po0.05.
RESULTS
Expression of VEGFs
Expression of all three VEGFs showed a positive cytoplasmic
staining in the breast cancer cells, with granular and hetero-
geneous staining in some specimens. Positive staining for VEGF-A
was detected in the normal mammary epithelial cells adjacent to
tumour, in the ECs and in the tumour-associated macrophages
(Figure 1A). Seventy-seven (40%) specimens of breast carcinomas
showed high expression of VEGF-A, with stronger staining
intensity found in the invasive component of the tumour and
vascular emboli. In many specimens, the staining intensity was
heterogeneous among tumour areas (Figure 1B). Consistent with
the findings of others (Nakamura et al, 2003a; Jennbacken et al,
2005), positive staining with VEGF-C and -D was observed in
the normal mammary epithelial cells, tumour-associated macro-
phages, stromal cells and ECs (Figure 1C)Vascular endothelial
cell growth factor-D showed positive staining in the vascular
smooth muscle fibres. Sixty-seven (37%) and 91 (44%) specimens
showed strong staining with VEGF-C and -D, respectively
(Figures 1C and D).
The relationship between expressions of the three growth factors
was analyzed. Specimens with high expression of VEGF-A found to
be significantly associated with high expression of VEGF-C
AB
D C
Figure 1 (A) Peritumoural area of a breast carcinoma section stained with VEGF-A showing positive staining in the endothelial cells (red arrow) and in
the macrophages (green arrow),  400. (B) Grade-III infiltrating breast carcinoma showing heterogeneous staining intensity for VEGF-A in the same
specimen; tumour sheets with weak staining intensity on the left and others with strong staining intensity on the right,  200. (C) VEGF-C-stained tumour
section showing strong positive staining in the tumour-associated macrophages (red arrow) and in the tumour cells,  400. (D) Grade-II infiltrating breast
carcinoma showing strong positive staining with VEGF-D,  100.
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s(P¼0.046) but not with expression of VEGF-D (P¼0.354). There
was, however, a significant association between expression of
VEGF-C and -D where 64% of cases with high expression of
VEGF-C had high expression of VEGF-D (P¼0.001), Table 1.
Relationships amongst expression of VEGFs, angiogenesis
and lymphangiogenesis
Lymph vessel density ranged from 0.015mm
 2 to 8.59mm
 2 with
a mean of 1.7mm
 270.1 and a median of 1.37. Fifty-five (31.1%)
specimens were characterised with a high LVD, Figure 2A. MVD
ranged from 1.0 to 7.6 with a mean of 2.570.09 and a median of
2.3. Seventy-six (42.9%) specimens were characterised with high
MVD, Figure 2B. The relationship amongst VEGF-A, -C and -D
expression, MVD and LVD are summarised in Table 2. Tumours
with high expression of VEGF-A were significantly associated with
both a higher MVD (Po0.001) and higher LVD (P¼0.013). Such
tumours had a mean MVD of 2.970.15 and a mean LVD of
1.570.11 compared to 2.270.11 and 2.070.19 for specimens with
low VEGF-A expression respectively. Similar findings were found
with tumours with high expression, of VEGF-C. Such tumours had
a mean MVD of 2.870.17 and a mean LVD of 2.270.22 compared
with 2.370.11 and 1.570.11 for patients with low VEGF-C
expression respectively (P¼0.002 for MVD and P¼0.014 for
LVD), such relationships are illustrated using box plots in Figure 3.
No statistical significant association was found between expression
of VEGF-D and LVD or with MVD.
Relationships between expression of VEGFs and
clinicopathological criteria
A comparison between low and high growth factor expressing
tumours was conducted to examine for potential associations with
clinicopathological characteristics (Table 2). High expression of
VEGF-A was significantly associated with tumours larger than
1.5cm (P¼0.038) and also with grade III tumours (Po0.001).
Sixty-four percent of breast carcinomas with negative oestrogen
receptors (ER) and 55% of those with negative progesterone
receptor (PR) status express significantly higher levels of VEGF-A
than hormonal receptor positive carcinomas (Po0.001 and
P¼0.004, respectively). A significant association was also found
with the presence of axillary LN (Po0.001) and presence of distant
metastasises (P¼0.010) but not with patients’ age.
A significant positive relationship between VEGF-C expression
and presence of LN metastasis (Po0.001) was detected.
Tumours larger than 1.5cm had a significantly higher level of
VEGF-C expression (P¼0.023) but unlike VEGF-A, no association
was found in relation to the tumour grade (P¼0.214) or with
the hormonal receptor status (P¼0.865 for ER and P¼0.624
for PR).
No significant association was found between expression of
VEGF-D and any of the clinicopathological criteria. However, a
larger proportion of tumours with high expression with VEGF-D
(54%) had LN metastasis compared to low expressing tumours
(42%) but was not statistically significant (P¼0.187).
Prognostic significance of growth factor expression
Kaplan–Meier analysis for OS and DFI were conducted to
investigate whether expression of VEGF-A, -C and -D had any
prognostic significance. From univariate analysis, high expression
of VEGF-A was significantly associated with shorter OS
(P¼0.029), Figure 4A. High expression of VEGF-C was signifi-
cantly associated with both shorter OS (P¼0.025 and DFI
(P¼0.028) (Figure 4B and C), however VEGF-D was neither
associated with DFI nor OS. Only VEGF-C retained significance
upon multivariate analysis, when adjusted for tumour size, tumour
grade and patient age (P¼0.047, hazard ratio 2.854; 95%
confidence interval 1.016–8.015).
Tumours were subsequently recategorised according to
expression of VEGF-A and -C into four groups; group (A);
tumours with low expression of both VEGF-A and -C, group (B);
tumours with high expression of VEGF-A, group (C); tumours
with high expression of VEGF-C and group (D); tumours with high
expression of both VEGF-A and -C. On survival analysis, tumours
with high expression of both VEGF-A and -C had the shortest OS
when compared with the other three groups (Po0.001)
(Figure 4D). The prognostic significance of LVD and MVD
will be a focus of a separate report examining the role of
lymphatic distribution, density and lymphovascular invasion in
relationship to clinicopathological criteria of tumours and
patients’ survival.
Table 1 Relationship between expression of VEGF-A, VEGF-C and
VEGF-D
VEGF-C no. (%) VEGF-D no. (%)
Low High P-value Low High P-value
VEGF-A
Low 75 (71) 31 (28) 61 (57) 45 (42)
High 39 (55) 32 (45) 0.046 35 (49) 36 (51) 0.354
VEGF-C
Low 73 (64) 41 (36)
High 23 (36) 40 (64) 0.001
VEGF-A¼vascular endothelial cell growth factor-A; VEGF-C¼vascular endothelial
cell growth factor-C. Bold values denotes statistical significance.
AB
Figure 2 (A) Infiltrating duct carcinoma of the breast stained with podoplanin showing multiple lymphatics at the peritumoural area with a lymphatic
invasion in one of the vessels (arrow),  200. (B) Infiltrating duct carcinoma of the breast stained with CD34 showing high MVD,  200.
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sDISCUSSION
The present report studied the expression of VEGF-A, -C and -D in
breast cancer and correlated results with the lymphangiogenic and
angiogenic characteristics of the tumours.
Vascular endothelial growth factor-A was originally identified
as an EC-specific growth factor that induces angiogenesis and
increases vascular permeability. It was found to be expressed in
normal human tissues including liver, kidney, adrenal glands, lung
and stomach (Ferrara and Davis-Smyth, 1997). In the study of
Brown et al, (1993), VEGF-A mRNA was detected in the breast
cancer cells whereas the corresponding proteins were found in
both tumour cells and the ECs, indicating that VEGF-A is secreted
by tumour cells then undergoes processing in the ECM to be
entrapped by the receptors on the surface of the ECs. In the
current report, and in agreement with such previous findings,
positive staining for VEGF-A was detected in the ECs, in the
normal epithelial mammary duct cells as well as in the tumour
cells.
Similar to findings reported by other studies on breast cancer
(Toi et al, 1995a; Hicklin and Ellis, 2005) and on other tumour
types (Han et al, 2001), tumours with high expression of VEGF-A
were characterised by a significantly higher MVD. This may be due
to the multiple effects of VEGF-A on ECs. Not only is it a potent
mitogenic factor but it also stimulates ECs to secrete cytokines
essential for cell migration and sprouting of new vessels. It has
long been supposed that VEGF-A had no association with
lymphangiogenesis, however, in two recent experimental studies,
VEGF-A overexpression was found to induce formation of new
lymph vessels and dilatation of pre-existing ones (Nagy et al, 2002;
Kunstfeld et al, 2004). This action was found to be mediated
through stimulation of VEGFR-2, a1b1 and a2b1 integrins on the
surface of LECs (Hong et al, 2004). Certain studies have reported a
significant relationship between VEGF-A expression and lymph-
angiogenesis in malignant lymphoma (Kadowaki et al, 2005) and
in lung carcinoma (Niki et al, 2000). The current study is the first,
to our knowledge, to report such a relationship in human breast
cancer, in that a significant association between VEGF-A expres-
sion and high LVD was observed. Such results suggest an
important role for VEGF-A in the induction of both angiogenesis
and lymphangiogenesis in breast cancer.
High expression of VEGF-A was found to be associated with
tumours larger than 1.5cm in size. This is in agreement with a
previous study on breast cancer (Toi et al, 1995a) and one on lung
cancer (Niki et al, 2000), where they found that high expression of
VEGF-A was not only associated with larger tumours but also with
Table 2 Association between expression of VEGFs with clinicopathological criteria, lymphangiogenesis and angiogenesis
No. of
patients
No. (%) of VEGF-A high-
expressing specimens P-value
No. (%) of VEGF-C high-
expressing specimens P-value
No. (%) of VEGF-D high-
expressing specimens P-value
Age
o50 years 51 18 (35) 15 (29) 23 (45)
450 years 126 53 (42) NS 48 (38) NS 58 (46) NS
Size
o1.5cm 65 19 (29) 16 (25) 28 (43)
41.5cm 112 52 (46) 0.038 47 (42) 0.023 53 (47) NS
Grade
I 45 9 (20) 9 (20) 22 (49)
II 62 19 (31) 29 (47) 30 (48)
III 70 43 (60) o0.001 25 (36) NS 29 (41) NS
LN status
Negative 125 36 (29) 31 (25) 53 (42)
Positive 52 35 (76) o0.001 32 (61) o0.001 28 (54) NS
NPI
Good 74 16 (22) 19 (26) 33 (45)
Intermediate 88 42 (47) 36 (41) 41 (47)
Poor 15 13 (87) o0.001 8 (53) 0.012 7 (47) NS
ER
Negative 56 37 (64) 19 (34) 28 (50)
Positive 112 34 (30) o0.001 41 (37) NS 49 (44) NS
PR
Negative 72 41 (55) 27 (38) 32 (44)
Positive 93 30 (32) 0.004 31 (33) NS 42 (45) NS
RR
No 136 55 (40) 42 (31) 59 (43)
Definite 41 16 (38) NS 21 (51) 0.025 22 (54) NS
MVD
Low 101 29 (29) 31 (31) 48 (48)
High 76 42 (55) o0.001* 32 (41) 0.002* 33 (43) NS*
LVD
Low 122 42 (35) 36 (29) 56 (46)
High 55 29 (51) 0.013* 27 (49) 0.014* 25 (46) NS*
LVI
Absent 108 36 (33) 33 (31) 48 (44)
Definite 69 35 (52) 0.028 30 (44) 0.107 33 (48) NS
DM
No 156 58 (37) 51 (33) 72 (45)
Definite 18 13 (71) 0.010 12 (67) 0.008 9 (50) NS
DM¼distant metastasis; ER¼oestrogen receptor; LN¼lymph node; LVD¼lymph vessel density; MVD¼microvessel density; NPI¼Nottingham prognostic index;
NS¼nonsignificant; PR¼progesterone receptor, RR¼regional recurrence. Statistical significance was tested using 2 2 table and w
2 test, except (*), where it was performed
using Mann–Whitney test. Bold values denotes statistical significance.
Prognostic significance of VEGF-A, -C and -D in breast cancer
RAA Mohammed et al
1096
British Journal of Cancer (2007) 96(7), 1092–1100 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
slarger metastatic deposits, likely through the growth factor
inducing a rich vascular network, and a correspondingly more
nutritious environment for tumour growth. The current study also
found that such tumours behaved more aggressively, as they
were significantly associated with the presence of LN metastasis
(Po0.001), distant metastasis (P¼0.01) and a poorer survival
(P¼0.029). These findings are similar to others, both in breast
cancer and other tumour types (Toi et al, 1995b; Linderholm et al,
1999; O-Charoenrat et al, 2001). Although the effect of VEGF-A
expression can be mediated by an increased vascular network, it
should be noted that the growth factor has also been shown to
increase breast cancer cell survival through direct action on
VEGFR-2 that has been found to be expressed on the surface of the
breast cancer cells. Vascular endothelial cell growth factor-A
production by, and VEGFR-2 activation on, the surface of tumour
cells indicates the presence of a distinct autocrine signalling loop
that enables breast cancer cells to promote their own growth and
survival by activation of VEGFR-2 (Weigand et al, 2005). The
findings in this study support others that have reported the
important role of VEGF-A in the progression of breast cancer; a
role mediated through angiogenesis and promotion of tumour cell
survival, and add the induction of lymphangiogenesis as another
possible mechanism.
Similar to previous reports (Gunningham et al, 2000), the
present study detected positive staining for VEGF-C and -D in
normal mammary epithelial cells at a weaker intensity than in the
surrounding invasive component suggesting a role in remodelling
lymphatic and blood vasculature in mammary stroma during the
menstrual cycle. It is known that the normal human mammary
gland undergoes a well-defined sequence of changes in both
epithelial and stromal compartments during the menstrual cycle,
with increased angiogenesis during the ovulatory phase under
effect of hormonal changes (Ferguson et al, 1992; Weinstein et al,
2005).
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vessels in the chick chorioallantoic membrane (Oh et al, 1997),
induced lymphangiogenesis around islet of Langerhans in the
pancreas which, normally, are not surrounded with lymphatics
(Mandriota et al, 2001), induced hyperplasia and dilatation of the
dermal lymphatics when overexpressed in transgenic mice (Jeltsch
et al, 1997) and increased LVD and LN metastasis in xenografted
breast cancer (Skobe et al, 2001). The present study reports a
significant association between expression of VEGF-C and LVD
similar to other findings reported in breast cancer (Nakamura
et al, 2005) and other tumour types (Yonemura et al, 1999;
Onogawa et al, 2004). This is mostly likely due to the stimulatory
effect of VEGF-C on VEGFR-3 and a9 b1 integrin on the LEC
surface. Stimulation of VEGFR-3 transmits potent mitogenic
signals into LECs, whereas activation of integrin induces redis-
tribution of the cellular actin cytoskeleton, leading to change in cell
shape and formation of pseudopodia enabling cells to migrate
eventually new lymphangiogenesis.
When processed through proteolysis in the ECM to mature
forms, VEGF-C has been reported to also activate VEGFR-2 on the
surface of the BECs, thereby inducing angiogenesis (Joukov et al,
1996). Such effects have been reported in experimental studies (Oh
et al, 1997), but has not been fully studied in human breast cancer.
Unlike a recent report by Hu et al (2005), the present study
indicates that tumours with high expression of VEGF-C are
significantly associated with a higher MVD, suggesting that VEGF-C
has an additional angiogenic effect in breast cancer and may
reflect active proteolysis found in the tumour microenvironment.
The study by Hu and co-workers found no such association,
however, such differences may reflect the different patient
population and the smaller number of specimens in the study
by Hu.
Similar to other studies (Nakamura et al, 2003b), when high
expression of VEGF-C was examined in relation to the clinico-
pathological characteristics and to patient survival, a significant
positive relationship was found with the presence of both LN
metastasis (Po0.001) and distant metastasis (P¼0.008). High
expression was also significantly associated with the occurrence of
regional recurrence (P¼0.025), and poorer OS (P¼0.028),
perhaps due to the potent ability of VEGF-C to induce both
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channels for dissemination of malignant cells.
Tumours which express high levels of both VEGF-A and -C were
found to have the worst prognosis when compared with tumours
expressing low levels of both factors or tumours expressing high
levels of either of the growth factors individually. These results
support the notion that the two VEGF family members may be
involved in tumour progression at two interrelated steps.
Evaluation of expression of both VEGF-A and -C may be an
important factor to identify breast cancer patients at higher risk of
recurrence and in need of adjuvant therapy.
VEGF-D is a relatively recent member of the VEGF family that
shares some structural and functional properties with VEGF-C
(Yamada et al, 1997). In experimental animal tumour models,
overexpression of VEGF-D was found to be significantly associated
with higher rate of LN metastasis, increased tumour angiogenesis
and larger tumour sizes (Stacker et al, 2001; Von Marschall et al,
2005; Yonemura et al, 2005). However, in human tumours, there is
variation amongst results. It has been reported to be significantly
associated with high LVD, LN metastasis and poorer survival in
gastric (Shida et al, 2005), endometrial (Yokoyama et al, 2003) and
colorectal carcinomas (White et al, 2002). In head and neck
tumours (O-Charoenrat et al, 2001), such relationships have not
been found. In other studies in breast and in lung carcinoma,
low levels of expression of VEGF-D was associated with poorer
prognosis (Niki et al, 2000; Koyama et al, 2003). In the current
study, there was a trend for tumours with higher VEGF-D
expression to have a higher rate of LN metastasis, regional
recurrence and distant metastasis, however, none of these reached
statistical significance. Similar findings were reported by Yang et al
(2002). In addition, no significant association was found between
expression of VEGF-D and either LVD or MVD. In a study on
breast cancer, a significant association was found between high
VEGF-D gene expression, using real-time polymerase chain
reaction and LVD (Choi et al, 2005). Such differences in results
may be due to the different methods in assessment of VEGF-D
expression. Although VEGF-D showed lymphangiogenic and
angiogenic effects in xenografted tumours, its biological role in
human breast cancer is still unclear and is in need of further study.
It is probable that VEGF-D plays different roles in different tumour
types.
In conclusion, it appears from this study of human breast
cancers that, as has been reported by in vitro studies, VEGF-A
plays a role in lymphangiogenesis. It also appears that breast
cancers, which express high levels of VEGF-A and -C are
characterised by greater angiogenesis and lymphangiogenesis
and are associated with the presence of both LN and distant
metastasis. Such tumours behave more aggressively as indicated by
the associations with shorter DFI and OS. Both growth factors
appear to play an important role in the progression of breast
carcinoma and to have a significant impact on patient prognosis.
Examination of expression of either VEGF-A and -C can be used to
identify a subset of breast cancer at higher risk for development of
recurrence and distant metastasis, with the recommendation that
both be assessed to further delineate those at highest risk.
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